TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018. Fitzgerald will resign as CFO and a director effective immediately while continuing to provide transition services. The company named John Tattory interim CFO, effective immediately.
Tattory brings more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies. His background includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics. He currently serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.
The leadership change comes at a critical time for TransCode as it advances its pipeline of novel cancer therapies. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
Fitzgerald’s retirement marks the end of a tenure that spanned nearly five years, during which TransCode transitioned into a clinical stage company and went public. His departure could raise questions about continuity in financial strategy, but the appointment of Tattory, with his extensive experience in life sciences and consulting, may help ensure a smooth transition. Tattory’s background in providing CFO services to private life science companies could be particularly valuable as TransCode navigates the complexities of clinical development and potential commercialization.
Investors and analysts will be watching closely to see how the change in financial leadership affects TransCode’s operations and strategic direction. The company’s ability to maintain momentum in its clinical programs and manage its financial resources effectively will be key to its success. For more information, the full press release is available at https://nnw.fm/8G3ik.
The latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ.
